# ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors

> **NCT05405595** · PHASE1,PHASE2 · RECRUITING · sponsor: **Adagene Inc** · enrollment: 186 (estimated)

## Conditions studied

- Advanced/Metastatic Solid Tumors

## Interventions

- **DRUG:** ADG126
- **DRUG:** Pembrolizumab (KEYTRUDA®)
- **DRUG:** Standard of Care (Trifluridine/Tipiracil-Bevacizumab)
- **DRUG:** Standard of care (Fruquintinib)

## Key facts

- **NCT ID:** NCT05405595
- **Lead sponsor:** Adagene Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-06-15
- **Primary completion:** 2026-10-31
- **Final completion:** 2027-04-30
- **Target enrollment:** 186 (ESTIMATED)
- **Last updated:** 2026-01-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05405595

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05405595, "ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05405595. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*